Similarly, the CXCR2-dependent recruitment of neutrophil granulocytes to the stroma of pancreatic cancer where they elicit high immunosuppressive activity and drive disease progression [57] could potentially be targeted by TRPC6 blockers. Here, CXCR2 is linked to pancreatic neoplasm.